For example, previous models of oncogene addiction or tumour suppressor hypersensitivity in leukemia and lymphoma have relied on transgenic mice where transactivator expression is controlled by the largely hematopoietic-specific Eμ or Vav promoters [8], [21], [22]. This evidence concerns the gene VAV1 and lymphoma.